Pfizer Reports Positive Data For MRNA-based Combination Vaccine Program Against Influenza & COVID-19

(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced positive results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

The companies plan to start a pivotal Phase 3 trial in the coming months.

For More Such Health News, visit rttnews.com